619. Acute Myeloid Leukemias: Disease Burden and Measurable Residual Disease in Prognosis and Treatment: Poster III

Single versus double 7 3 induction with 60 versus 90 mg m2 daunorubicin in newly diagnosed AML Does it matter for NPM1 MRD

Clinical feasibility of peripheral blood–based MRD monitoring using the miselect R AML MRD assay in Acute Myeloid Leukemia

High prognostic value of NGS based measurable residual FLT3 ITD in AML patients positive for FLT3 ITD treated with ponatinib in combination with cytarabine in first complete remission

Outcomes of NPM1 mutated AMLs in first hematological relapse and prognostic value of MRD